Cargando…

509. A Comparison of Tocilizumab and Baricitinib for Hospitalized Patients with Severe COVID-19

BACKGROUND: Baricitinib (BARI) and tocilizumab (TOCI) are two FDA-approved immunomodulating agents for the treatment of COVID-19 patients with worsening respiratory status, but early studies suggest no differences in outcomes between the two therapies. METHODS: This is a single-center retrospective...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aytoda, Priyanka, Albrecht, Benjamin, Green, Sarah B, Harris, Gavin, Busch, Lindsay M, Sexton, Mary Elizabeth, Wiley, Zanthia, Rimawi, Ramzy H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678578/ http://dx.doi.org/10.1093/ofid/ofad500.578

Ejemplares similares

2648. Taming the Cytokine Storm: Baricitinib versus Tocilizumab for COVID-19 Hyperinflammation
por: Radziszewski, Skyler, et al.
Publicado: (2023)

513. Evaluating the safety of baricitinib versus tocilizumab in hospitalized patients with COVID-19
por: Brickel, Kendall, et al.
Publicado: (2023)

509. Comparision of CD4+ T Cells in Patients with Severe vs Critical COVID -19
por: Gomez-Gomez, Brenda, et al.
Publicado: (2020)

Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19
por: Masiá, Mar, et al.
Publicado: (2021)

Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial
por: Karampitsakos, Theodoros, et al.
Publicado: (2023)

Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study
por: Bryushkova, Ekaterina A., et al.
Publicado: (2022)

Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19
por: Foo, Hong, et al.
Publicado: (2023)

Combined administration of inhaled DNase, baricitinib and tocilizumab as rescue treatment in COVID-19 patients with severe respiratory failure
por: Gavriilidis, Efstratios, et al.
Publicado: (2022)

Tocilizumab vs. baricitinib in hospitalized severe COVID-19 patients: results from a real-world cohort
por: Karolyi, Mario, et al.
Publicado: (2022)

Efficacy of Noncarbapenem β-Lactams Compared to Carbapenems for Extended-Spectrum β-Lactamase–Producing Enterobacterales Urinary Tract Infections
por: Anderson, Daniel T, et al.
Publicado: (2022)

509. Spatio-Temporal Clustering of CDI Cases at the University of Iowa Hospitals and Clinics
por: Pai, Shreyas, et al.
Publicado: (2018)

509. The Prevalence of Carbapenem-Resistant Enterobacteriaceae (CRE) in a Community Hospital Setting
por: Lewis, Sally, et al.
Publicado: (2019)

Reductions in Postdischarge Clostridioides difficile Infection after an Inpatient Health System Fluoroquinolone Stewardship
por: Ashley Jones, K., et al.
Publicado: (2021)

498. Baricitinib in Patients with Severe Pneumonia due to COVID-19 in Veracruz, Mexico
por: Del Carpio-Orantes, Luis, et al.
Publicado: (2021)

The effects of combination-therapy of tocilizumab and baricitinib on the management of severe COVID-19 cases: a randomized open-label clinical trial
por: Dastan, Farzaneh, et al.
Publicado: (2023)

Comparative Efficacy of Tocilizumab and Baricitinib Administration in COVID-19 Treatment: A Retrospective Cohort Study
por: Kojima, Yuichi, et al.
Publicado: (2022)

1404. The FilmArray Meningitis/Encephalitis (FA ME) May Be of Higher Yield in the Immunocompromised Patient Population
por: Mehta, Nirja, et al.
Publicado: (2019)

Initiation of Tocilizumab or Baricitinib Were Associated With Comparable Clinical Outcomes Among Patients Hospitalized With COVID-19 and Treated With Dexamethasone
por: Wong, Carlos K. H., et al.
Publicado: (2022)

Treatment of severe alopecia areata with baricitinib
por: Olamiju, Brianna, et al.
Publicado: (2019)

189. Validating a Hospitalist-Specific Antibiotic Prescribing Metric across Four Acute Care Hospitals
por: Howard-Anderson, Jessica, et al.
Publicado: (2020)

Tocilizumab Versus Baricitinib in Patients Hospitalized With COVID-19 Pneumonia and Hypoxemia: A Multicenter Retrospective Cohort Study
por: Roddy, John, et al.
Publicado: (2022)

PM509. Homeostatic synaptic plasticity of parvalbumin-positive inhibitory interneurons confers cognitive dysfunction in medial prefrontal cortex.
por: Shin, Jae Jin, et al.
Publicado: (2016)

Baricitinib vs tocilizumab treatment for hospitalized adult patients with severe COVID-19 and associated cytokine storm: a prospective, investigational, real-world study
por: Lakatos, Botond, et al.
Publicado: (2022)

1766. An Integrated Infectious Disease and Critical Care Staffing Model for Clinical Care of Special Pathogens
por: Busch, Lindsay M, et al.
Publicado: (2023)

SAT-509 Sudden Onset of Malabsorption
por: Mroueh, Gabriela, et al.
Publicado: (2020)

Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: A comparison using systematic review and meta-analysis
por: Cherian, Jerin Jose, et al.
Publicado: (2022)

Using the Surviving Sepsis Coronavirus Disease 2019 Guidelines—Anything New Yet?
por: Rimawi, Ramzy H.
Publicado: (2020)

Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

x509-free access to WLCG resources
por: Short, H, et al.
Publicado: (2017)

WLCG Authorisation from X.509 to Tokens
por: Bockelman, Brian, et al.
Publicado: (2020)

509 Pilot Projects as Catalysts for Research Initiatives
por: Patel, Milan, et al.
Publicado: (2022)

Fr509 COVID-19 OUTCOMES AMONG RACIAL AND ETHNIC MINORITY INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASES IN THE UNITED STATES
por: Agrawal, Manasi, et al.
Publicado: (2021)

1114. Comparative analysis between Polymerized Type I Collagen and Baricitinib as potential treatment for COVID-19
por: Carpio-Orantes, Luis Del, et al.
Publicado: (2022)

Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study
por: Rosas, José, et al.
Publicado: (2022)

Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study
por: Rosas, José, et al.
Publicado: (2022)

Tocilizumab and Baricitinib for Recovery From Acute Exacerbation of Combined Pulmonary Fibrosis and Emphysema Secondary to COVID-19 Infection: A Case Report
por: Kai, Yoshiro, et al.
Publicado: (2022)

REMDESIVIR PLUS DEXAMETHASONE VS TOCILIZUMAB OR BARICITINIB SUPPLEMENTATION INITIATED INSIDE 48 HOURS OF INDEX COVID-19 HOSPITALIZATION IN ICU PATIENTS
por: WILLIAMS, STEPHANIE N, et al.
Publicado: (2022)

Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis
por: Albuquerque, Arthur M., et al.
Publicado: (2023)

COVID-19 Vaccines
por: Hahn, William O., et al.
Publicado: (2022)

Application of Baricitinib in Dermatology
por: Zhang, Jingya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2cnsvf66118mavet0od2mqojme